Subscribe To
ADIL / All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
ADIL News
By Zacks Investment Research
October 30, 2023
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. Thi more_horizontal
By Accesswire
October 19, 2023
Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th
CHARLOTTESVILLE, VA / ACCESSWIRE / October 19, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharma more_horizontal
By GlobeNewsWire
September 5, 2023
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clini more_horizontal
By Zacks Investment Research
April 4, 2023
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year. more_horizontal
By Seeking Alpha
August 22, 2022
Adial Clinical Trial: A Fluff Or A Win?
Onward Phase III Clinical Trial of Adial Pharmaceutical's AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study more_horizontal